Stocks · News reference
FDA approves Cosette Pharmaceuticals' EVOXAC
– – New Oral Solution Formulation Developed for Patients Living with Sjögren’s Disease demonstrates Cosette's expanding capabilities in product development and innovation – –– – Product Expected to be Commercially
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Hamilton Lane INC (HLNE)
Filed: 2026-10-15 AccNo: 0001433642-26-000048 Size: 166 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
UBS Maintains Buy on Hamilton Lane, Lowers Price Target to $115
UBS analyst Michael Brown maintains Hamilton Lane (NASDAQ:HLNE) with a Buy and lowers the price target from $131 to $115.